In recent years, increasing evidence has defined the value of OPN as a candidate biomarker and drug target for many types of cancers, such as hepatocellular carcinoma (HCC) [2], breast cancer [3], ovarian cancer [4], cervical cancer [5], and gastric cancer [5]. This evidence concerns the gene SPP1 and breast carcinoma.